减重神药再无"霸主"？清华团队一针见效新技术问世，改造免疫细胞实现持久控糖瘦身双效

Core Viewpoint - The article discusses a groundbreaking research study that introduces a long-lasting CAR-T cell platform for the delivery of biologics, specifically targeting chronic diseases like obesity and diabetes, offering a potential solution for patients requiring lifelong treatment [7][8][20]. Group 1: Research Breakthroughs - The research team from Tsinghua University developed a revolutionary long-lived CAR-T cell, named GD2TIF, which can achieve sustained release of GLP-1, a key drug for obesity and diabetes, with a single injection [8][18]. - This innovative approach allows for long-term management of chronic diseases, potentially eliminating the need for repeated injections that are common with current peptide/protein biologics [7][20]. Group 2: Mechanism and Advantages - The GD2TIF cells can maintain stable levels in the body without the need for chemotherapy pre-treatment, which is often risky for non-cancer patients [16][17]. - The platform targets GD2, a tumor-associated antigen, ensuring safety by minimizing off-target effects, as GD2 is highly expressed in certain tumors but not in normal tissues [16][17]. Group 3: Clinical Implications - In animal models, a single infusion of GD2TIF cells secreting GLP-1 resulted in sustained weight management and normal blood sugar levels, meeting clinical "cure" standards for obesity and diabetes [18][20]. - The research indicates that this method could provide a cost-effective alternative to traditional biologic therapies, which often require ongoing treatment and frequent medical visits [20].